Viking Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and announced a $105 price target.
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and announced a $105 price target.
June 27, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics shares are trading higher following Morgan Stanley's initiation of coverage with an Overweight rating and a $105 price target.
Morgan Stanley's initiation of coverage with an Overweight rating and a high price target is a strong positive signal for Viking Therapeutics, likely driving short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100